» Articles » PMID: 18239669

Gut Microbiota: a Potential New Territory for Drug Targeting

Overview
Specialty Pharmacology
Date 2008 Feb 2
PMID 18239669
Citations 182
Authors
Affiliations
Soon will be listed here.
Abstract

The significant involvement of the gut microbiota in human health and disease suggests that manipulation of commensal microbial composition through combinations of antibiotics, probiotics and prebiotics could be a novel therapeutic approach. A systems perspective is needed to help understand the complex host-bacteria interactions and their association with pathophysiological phenotypes so that alterations in the composition of the gut microbiota in disease states can be reversed. In this article, we describe the therapeutic rationale and potential for targeting the gut microbiota, and discuss strategies and systems-oriented technologies for achieving this goal.

Citing Articles

Correlation between gut microbiota dysbiosis, metabolic syndrome and breast cancer.

Abdelqader E, Mahmoud W, Gebreel H, Kamel M, Abu-Elghait M Sci Rep. 2025; 15(1):6652.

PMID: 39994329 PMC: 11850770. DOI: 10.1038/s41598-025-89801-8.


The Role of the Gut Microbiota in Health, Diet, and Disease with a Focus on Obesity.

Ma Z, Lee Y Foods. 2025; 14(3).

PMID: 39942085 PMC: 11817362. DOI: 10.3390/foods14030492.


An emerging probiotic with liver health benefits for smokers.

Jia W, Zheng X Life Metab. 2025; 2(1):loac033.

PMID: 39872509 PMC: 11749835. DOI: 10.1093/lifemeta/loac033.


5-aminosalicylic acid alleviates colitis and protects intestinal barrier function by modulating gut microbiota in mice.

Wang J, Wang X, Jiang M, Lang T, Wan L, Dai J Naunyn Schmiedebergs Arch Pharmacol. 2024; .

PMID: 39352537 DOI: 10.1007/s00210-024-03485-x.


Intestinal and hepatic benefits of BBR-EVO on DSS-induced experimental colitis in mice.

Wang W, Han Y, Yin W, Wang Q, Wu Y, Du M Front Microbiol. 2024; 15:1428327.

PMID: 39296302 PMC: 11408294. DOI: 10.3389/fmicb.2024.1428327.